menu
    • menu
    [{"orgOrder":0,"company":"Yangtze River Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Levornidazole Disodium Phosphate","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Yangtze River Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yangtze River Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Yangtze River Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Yangtze River Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Meloxicam","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Yangtze River Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yangtze River Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Yangtze River Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Yangtze River Pharmaceutical Group","sponsor":"Yangtze River Pharmaceutical Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Yangtze River Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yangtze River Pharmaceutical Group \/ Yangtze River Pharmaceutical Group","highestDevelopmentStatusID":"1","companyTruncated":"Yangtze River Pharmaceutical Group \/ Yangtze River Pharmaceutical Group"},{"orgOrder":0,"company":"Yangtze River Pharmaceutical Group","sponsor":"Yangtze River Pharmaceutical Group","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Zhengyuan","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Yangtze River Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Yangtze River Pharmaceutical Group \/ Yangtze River Pharmaceutical Group","highestDevelopmentStatusID":"11","companyTruncated":"Yangtze River Pharmaceutical Group \/ Yangtze River Pharmaceutical Group"},{"orgOrder":0,"company":"Yangtze River Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Tunodafil HCl","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Yangtze River Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yangtze River Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Yangtze River Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Yangtze River Pharmaceutical Group","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Yangtze River Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yangtze River Pharmaceutical Group \/ Alvotech","highestDevelopmentStatusID":"1","companyTruncated":"Yangtze River Pharmaceutical Group \/ Alvotech"},{"orgOrder":0,"company":"Yangtze River Pharmaceutical Group","sponsor":"Nanfang Hospital, Southern Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dezocine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Yangtze River Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yangtze River Pharmaceutical Group \/ Nanfang Hospital, Southern Medical University","highestDevelopmentStatusID":"11","companyTruncated":"Yangtze River Pharmaceutical Group \/ Nanfang Hospital, Southern Medical University"},{"orgOrder":0,"company":"Yangtze River Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Yangtze River Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yangtze River Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Yangtze River Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Yangtze River Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Meloxicam","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase I","graph3":"Yangtze River Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yangtze River Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Yangtze River Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Yangtze River Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nabufine HCl","moa":"Kappa\/Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Yangtze River Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yangtze River Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Yangtze River Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Yangtze River Pharmaceutical Group","sponsor":"The First Affiliated Hospital of Zhengzhou University | Beijing Haisha Consulting Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Levornidazole Disodium Phosphate","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Yangtze River Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yangtze River Pharmaceutical Group \/ The First Affiliated Hospital of Zhengzhou University | Beijing Haisha Consulting Co., Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Yangtze River Pharmaceutical Group \/ The First Affiliated Hospital of Zhengzhou University | Beijing Haisha Consulting Co., Ltd"}]

    Find Clinical Drug Pipeline Developments & Deals by Yangtze River Pharmaceutical Group

    Menu

    Yangtze River Pharmaceutical Group

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Yangtze River Pharmaceutical Group

                            China arrow
                            Formnext Forum
                            Not Confirmed

                            Yangtze River Pharmaceutical Group

                            China arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levornidazole Disodium Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : The First Affiliated Hospital of Zhengzhou University | Beijing Haisha Consulting Co., Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Levornidazole Injection PK and Safety In Renal Impaired and Normal Adults

                            Details : Levornidazole Disodium Phosphate is a Antibiotic drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Bacteria, Anaerobic Infections.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            June 24, 2025

                            Lead Product(s) : Levornidazole Disodium Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : The First Affiliated Hospital of Zhengzhou University | Beijing Haisha Consulting Co., Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Yangtze River Pharmaceutical Group

                            China arrow
                            Formnext Forum
                            Not Confirmed

                            Yangtze River Pharmaceutical Group

                            China arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Safety and Efficacy of Nalbuphine Versus Morphine for Postoperative Analgesia

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            April 29, 2025

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Yangtze River Pharmaceutical Group

                            China arrow
                            Formnext Forum
                            Not Confirmed

                            Yangtze River Pharmaceutical Group

                            China arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Meloxicam

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surg...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 01, 2025

                            Lead Product(s) : Meloxicam

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Yangtze River Pharmaceutical Group

                            China arrow
                            Formnext Forum
                            Not Confirmed

                            Yangtze River Pharmaceutical Group

                            China arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Meloxicam

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability and Pharmacokinetics of Meloxicam Nanocrystal Injection in Healthy Subjects

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 30, 2025

                            Lead Product(s) : Meloxicam

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Yangtze River Pharmaceutical Group

                            China arrow
                            Formnext Forum
                            Not Confirmed

                            Yangtze River Pharmaceutical Group

                            China arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nabufine HCl

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetic Study of Single and Multiple Intravenous Administration of Nalbuphine Hydrochloride Injection ...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 30, 2025

                            Lead Product(s) : Nabufine HCl

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Yangtze River Pharmaceutical Group

                            China arrow
                            Formnext Forum
                            Not Confirmed

                            Yangtze River Pharmaceutical Group

                            China arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levornidazole Disodium Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Levornidazole Disodium Phosphate for Injection vs. Ornidazole in Treatment of Postoperative Intra-A...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            February 17, 2025

                            Lead Product(s) : Levornidazole Disodium Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Yangtze River Pharmaceutical Group

                            China arrow
                            Formnext Forum
                            Not Confirmed

                            Yangtze River Pharmaceutical Group

                            China arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dezocine

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Nanfang Hospital, Southern Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Dezocine Combined With Sufentanil on the Quality of Postoperative Recovery and Analgesic Effect in P...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 03, 2024

                            Lead Product(s) : Dezocine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Nanfang Hospital, Southern Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Yangtze River Pharmaceutical Group

                            China arrow
                            Formnext Forum
                            Not Confirmed

                            Yangtze River Pharmaceutical Group

                            China arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zhengyuan

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase IV

                            Recipient : Qiang Fu

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cancer-related Fatigue in Patients With Breast Cancer Treatment With Zhengyuan Capsules

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            April 24, 2024

                            Lead Product(s) : Zhengyuan

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase IV

                            Recipient : Qiang Fu

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Yangtze River Pharmaceutical Group

                            China arrow
                            Formnext Forum
                            Not Confirmed

                            Yangtze River Pharmaceutical Group

                            China arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tunodafil HCl

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of the Interaction of Tunodafil Hydrochloride Tablets and Alcohol

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 04, 2023

                            Lead Product(s) : Tunodafil HCl

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Yangtze River Pharmaceutical Group

                            China arrow
                            Formnext Forum
                            Not Confirmed

                            Yangtze River Pharmaceutical Group

                            China arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexmedetomidine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Recipient : Harbin Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 03, 2021

                            Lead Product(s) : Dexmedetomidine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Harbin Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth